Philips and Diagnostics Development win European Union 'Horizon Prize - Better Use of Antibiotics'

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a leader in HealthTech, and Diagnostics Development, a P&M Venge company spin-off from Uppsala University (Sweden), have demonstrated a proof-of-concept for the rapid and reliable detection of bacterial infection. The test is based on Philips' Minicare I-20 handheld diagnostics platform and detects the human neutrophil lipocalin (HNL) biomarker in a single 'finger-prick' drop of blood. In recognition of the test's ability to distinguish between acute bacterial and viral infections, and thereby mitigate the unnecessary use of antibiotics, the two companies were awarded the European Union 'Horizon Prize - Better Use of Antibiotics' during a special award ceremony on the evening of February 6, 2017.

Antimicrobial agents - such as antibiotics - have dramatically reduced the number of deaths from infectious diseases since their introduction 70 years ago. However, through their overuse and misuse, many micro-organisms have become resistant to them. It is estimated that each year this growing antimicrobial resistance (AMR) causes around 25,000 deaths and accounts for over EUR 1.5 billion in healthcare costs and productivity losses in Europe alone, making it one of the greatest challenges facing society today. To boost development and bring new and innovative players to AMR research, the EU issued a prize for the individual or team that most effectively meets the following challenge: "to develop a rapid test that will allow healthcare providers to distinguish at the point of care between patients with upper respiratory tract infections that require antibiotics and those that can be treated safely without antibiotics".

"This prize is a great recognition of how collaboration can lead to innovative diagnostic solutions that improve patient care," said Marcel van Kasteel, CEO of Handheld Diagnostics at Philips. "The HNL program for detection of bacterial infections perfectly fits with our 'open platform' strategy of bringing innovative biomarker content onto the Minicare I-20 platform in order to offer healthcare professionals a panel of relevant tests for acute settings. Activities are ongoing to further develop the HNL test for eventual implementation in routine clinical practice.

"In various studies, HNL has demonstrated superior performance compared to biomarkers currently used to diagnose bacterial infection," said Per Venge, CEO of P&M Venge AB. "I am therefore very excited that we have been able to successfully demonstrate the detection of HNL on the Minicare I-20 using blood samples from patients with upper respiratory tract infections in the Uppsala University hospital, where within a few minutes patients with a bacterial infection could clearly be distinguished from those with viral infections or other conditions."

Based on Philips' proprietary biosensor technology, the Minicare I-20 handheld diagnostics platform is designed to detect multiple target molecules at very low concentrations in a single 'finger-prick' blood sample, and display the results on a handheld analyzer within minutes. Philips already has CE marking for its Minicare I-20 based cardiac troponin I (cTnI) blood test for the rapid point-of-care diagnosis of heart attack, and it is currently developing further tests for acute care settings.

Minicare I-20 is simple and easy to use by non-laboratory staff. The analyzer's built-in connectivity allows direct transfer of the data to laboratory and hospital information systems to update patient files, while integrated calibration and fail-safe functionalities ensure the robustness and accuracy needed for confident on-the-spot decision making.

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries.

Most Popular Now

Designing Soft Robots: Ethics-Based Guid…

Soft-bodied robots offer the possibility for social engagement, and novel tactile human-robot interactions that require careful consideration of the potential for misplaced emotional attachments and personally and socially destructive behavior...

Breathable, Wearable Electronics on Skin…

A hypoallergenic electronic sensor can be worn on the skin continuously for a week without discomfort, and is so light and thin that users forget they even have it on...

Google Searches can be Used to Track Den…

An analytical tool that combines Google search data with government-provided clinical data can quickly and accurately track dengue fever in less-developed countries, according to new research published in PLOS Computational...

IMI Launches EUR 130 Million Calls for P…

The Innovative Medicines Initiative (IMI) is launching two new Calls for proposals with topics on Alzheimer's disease, big data, vaccines, autoimmune disease, the blood-brain barrier, drug development, and the exploitation...

The Danish Reference Genome

After close to 5 years of work, the GenomeDenmark consortium has now finalized the efforts to establish a Danish Reference genome. The result is a reference of unrivalled quality and...

NHS Fife Connects Hospitals Following Su…

Ten hospitals across Fife are using real-time information to deliver better co-ordinated care for thousands of patients, following the successful go-live of InterSystems TrakCare®. Frontline staff in all of NHS...

eHealth Innovation Days 2017

7 - 8 September 2017, Flensburg, Germany. The 2nd eHealth Innovation Days will gather the different professionals and stakeholders concerned with eHealth: developers, healthcare professionals, researchers, policy makers, citizens as well...

Philips and Italian Fatebenefratelli Hos…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and the historic San Giovanni Calibita Fatebenefratelli Hospital in Rome today announced a long-term strategic partnership to introduce...

Philips to Strengthen its Ultrasound Bus…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has signed an agreement to acquire TomTec Imaging Systems GmbH (TOMTEC), a leading provider of intelligent image analysis...